[go: up one dir, main page]

PE20110711A1 - Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma - Google Patents

Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma

Info

Publication number
PE20110711A1
PE20110711A1 PE2011001056A PE2011001056A PE20110711A1 PE 20110711 A1 PE20110711 A1 PE 20110711A1 PE 2011001056 A PE2011001056 A PE 2011001056A PE 2011001056 A PE2011001056 A PE 2011001056A PE 20110711 A1 PE20110711 A1 PE 20110711A1
Authority
PE
Peru
Prior art keywords
quinuclidin
carboxamide
thiophene
benzo
chloro
Prior art date
Application number
PE2011001056A
Other languages
English (en)
Inventor
Gerhard Koenig
Richard Chesworth
Gideon Shapiro
Original Assignee
Envivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110711(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Envivo Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of PE20110711A1 publication Critical patent/PE20110711A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL)BENZO[b]TIOFENO-2-CARBOXAMIDA EN UNA CANTIDAD DE 0,3MG A 3MG EN PESO DE LA COMPOSICION. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA TRATAR LA ESQUIZOFRENIA, TRASTORNO DELIRANTE, ENFERMEDAD DE ALZHEIMER, ENTRE OTROS, ASI COMO PARA MEJORAR LA COGNICION, APRENDIZAJE VISUAL, FUNCION VISOMOTORA, VELOCIDAD DE PROCESAMIENTO, MEMORIA A LARGO PLAZO, ENTRE OTROS, EN DONDE DICHO PROCESO COMPRENDE ADMINISTRAR (R)-7-CLORO-N-(QUINUCLIDIN-3-IL)BENZO[b]TIOFENO-2-CARBOXAMIDA A UNA DOSIS DIARIA ENTRE 0,3MG Y 3MG
PE2011001056A 2008-11-19 2009-11-19 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma PE20110711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11610608P 2008-11-19 2008-11-19

Publications (1)

Publication Number Publication Date
PE20110711A1 true PE20110711A1 (es) 2011-10-11

Family

ID=41786120

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001056A PE20110711A1 (es) 2008-11-19 2009-11-19 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma

Country Status (34)

Country Link
US (6) US8642638B2 (es)
EP (4) EP2889033B1 (es)
JP (6) JP5272080B2 (es)
KR (3) KR20140146216A (es)
CN (3) CN102281878A (es)
AU (1) AU2009316557B2 (es)
BR (1) BRPI0922057A2 (es)
CA (3) CA2894860C (es)
CL (3) CL2011001178A1 (es)
CO (1) CO6400190A2 (es)
CR (1) CR20110267A (es)
CY (3) CY1113671T1 (es)
DK (3) DK2355822T3 (es)
EC (1) ECSP11011076A (es)
ES (3) ES2673016T3 (es)
HR (3) HRP20130007T1 (es)
HU (2) HUE037938T2 (es)
IL (5) IL212921A (es)
LT (1) LT2889033T (es)
MX (1) MX2011005270A (es)
MY (2) MY173229A (es)
NZ (2) NZ593467A (es)
PE (1) PE20110711A1 (es)
PH (2) PH12014501629A1 (es)
PL (3) PL2540297T3 (es)
PT (3) PT2889033T (es)
RS (1) RS52583B (es)
RU (3) RU2532327C2 (es)
SG (1) SG10201504102QA (es)
SI (3) SI2889033T1 (es)
SM (3) SMT201800308T1 (es)
TR (1) TR201807944T4 (es)
WO (1) WO2010059844A1 (es)
ZA (1) ZA201104044B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
KR101698250B1 (ko) 2010-05-17 2017-01-19 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
WO2012074799A1 (en) * 2010-11-18 2012-06-07 Envivo Pharmaceuticals, Inc. Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
US20140155429A1 (en) * 2011-05-09 2014-06-05 Envivo Pharmaceuticals, Inc. Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
EP2725906A4 (en) * 2011-07-01 2015-02-18 Envivo Pharmaceuticals Inc LIMIT COGNITIVE DEFICIT TREATMENT METHODS
RU2635522C2 (ru) * 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
CA3053916A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de) 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de) 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US5198437A (en) 1987-12-10 1993-03-30 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and amides
ZA889166B (en) 1987-12-10 1990-05-30 Duphar Int Res 1,7-annelated indolecarboxylic acid esters and -amides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5114947A (en) 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de) 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
SK282366B6 (sk) 1994-08-24 2002-01-07 Astra Aktiebolag Spiro-azabicyklická zlúčenina, farmaceutický prípravok s jej obsahom, spôsob prípravy, medziprodukty tohto spôsobu a jej použitie v medicíne
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SK284994B6 (sk) 1997-05-30 2006-04-06 Neurosearch A/S Deriváty 8-azabicyklo[3.2.1]okt-2-énu, spôsob ich prípravy a ich použitie
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
AU6394399A (en) 1998-09-18 2000-04-10 Rockefeller University, The Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en) 1999-11-08 2002-07-09 Research Triangle Institute Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
EP1233979A1 (en) 1999-12-01 2002-08-28 Ortho-McNeil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
CA2393538A1 (en) 1999-12-14 2001-06-21 Pharmacia & Upjohn Company Human ion channels
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr) 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de) 2000-09-12 2002-03-21 Merck Patent Gmbh (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003018586A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2003081978A (ja) 2001-09-10 2003-03-19 Mitsubishi Pharma Corp スピロ環式化合物およびその医薬用途
US20030105089A1 (en) 2001-09-12 2003-06-05 Wishka Donn G. Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
AP1635A (en) 2001-10-02 2006-07-14 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
EP1438308A1 (en) 2001-10-26 2004-07-21 PHARMACIA & UPJOHN COMPANY N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
JP2005511613A (ja) 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
MXPA04004373A (es) 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
FR2832714B1 (fr) 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10162442A1 (de) 2001-12-19 2003-07-03 Bayer Ag Monocyclische N-Aryl-amide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
AU2003219690A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1476448A2 (en) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds for the treatment of disease
AU2003214936A1 (en) 2002-02-20 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2003095976A2 (en) 2002-05-09 2003-11-20 Memory Pharmaceuticals Corporation Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
JP2006503811A (ja) 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003249532A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
PL377777A1 (pl) 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2008523058A (ja) 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
WO2007038367A1 (en) 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
GEP20125405B (en) 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ATE503754T1 (de) 2007-10-01 2011-04-15 Comentis Inc 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
BRPI0820418A2 (pt) 2007-11-21 2015-05-19 Abbott Lab "derivados de alcano azabicíclico substituído com biarila como moduladores da atividade do receptor nicotínico de acetilcolina"
EA019571B1 (ru) 2008-04-29 2014-04-30 Фарнекст Применение сульфизоксазола для лечения болезни альцгеймера
CA2722453C (en) 2008-04-29 2018-03-20 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
NZ589304A (en) 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
WO2010075635A1 (en) 2008-12-30 2010-07-08 Ramot At Tel Aviv University Ltd. Combination therapies using nap
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP3395372B1 (en) 2009-02-20 2022-04-06 EnhanX Biopharm Inc. Glutathione-based drug delivery system
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
DK2419104T3 (en) 2009-04-13 2018-02-05 Theravance Biopharma R&D Ip Llc Combinations of 5-HT4 Receptor Agonists and Acetylcholinesterase Inhibitors to Treat Cognitive Disorders
JP2012529432A (ja) 2009-06-05 2012-11-22 リンク・メディスン・コーポレーション アミノピロリジノン誘導体及びその使用
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions

Also Published As

Publication number Publication date
CL2011001178A1 (es) 2011-10-14
HRP20130007T1 (hr) 2013-01-31
RS52583B (sr) 2013-04-30
JP2020040977A (ja) 2020-03-19
HRP20180942T1 (hr) 2018-08-10
CO6400190A2 (es) 2012-03-15
PH12014501629B1 (en) 2016-01-18
CL2018001420A1 (es) 2018-09-28
JP2015083574A (ja) 2015-04-30
US8815933B2 (en) 2014-08-26
AU2009316557A1 (en) 2010-05-27
RU2011124515A (ru) 2012-12-27
US20130137717A1 (en) 2013-05-30
IL242034A (en) 2017-12-31
BRPI0922057A2 (pt) 2015-12-15
DK2889033T3 (en) 2018-07-02
IL212921A (en) 2015-11-30
PH12014501629A1 (en) 2016-01-18
CY1121607T1 (el) 2020-05-29
CA3017886A1 (en) 2010-05-27
JP5674854B2 (ja) 2015-02-25
ES2673016T3 (es) 2018-06-19
US20110288119A1 (en) 2011-11-24
CN102281878A (zh) 2011-12-14
SMT201300003B (it) 2013-05-06
JP2018039818A (ja) 2018-03-15
LT2889033T (lt) 2018-07-10
EP2540297A1 (en) 2013-01-02
US20140155430A1 (en) 2014-06-05
EP2355822A1 (en) 2011-08-17
CN105687191A (zh) 2016-06-22
JP2012509347A (ja) 2012-04-19
EP2355822B1 (en) 2012-10-10
SI2540297T1 (sl) 2015-08-31
CL2017001853A1 (es) 2018-05-11
TR201807944T4 (tr) 2018-06-21
PL2355822T3 (pl) 2013-03-29
CN105687190A (zh) 2016-06-22
EP2889033A1 (en) 2015-07-01
ECSP11011076A (es) 2011-09-30
MX2011005270A (es) 2011-08-03
SG10201504102QA (en) 2015-06-29
MY173229A (en) 2020-01-07
DK2355822T3 (da) 2013-01-28
EP3357495B1 (en) 2019-12-25
ES2396300T3 (es) 2013-02-20
CA2744278C (en) 2015-09-08
CA2894860A1 (en) 2010-05-27
AU2009316557B2 (en) 2015-08-27
CR20110267A (es) 2011-10-13
SMT201800308T1 (it) 2018-09-13
PL2889033T3 (pl) 2018-10-31
SI2889033T1 (en) 2018-08-31
SMT201500167B (it) 2015-09-07
KR20180011888A (ko) 2018-02-02
PT2889033T (pt) 2018-06-18
ES2541528T3 (es) 2015-07-21
EP2889033B1 (en) 2018-03-21
US20140148479A1 (en) 2014-05-29
KR20110091549A (ko) 2011-08-11
RU2014122858A (ru) 2015-12-10
MY159826A (en) 2017-02-15
RU2532327C2 (ru) 2014-11-10
JP5272080B2 (ja) 2013-08-28
RU2662560C2 (ru) 2018-07-26
JP2013166771A (ja) 2013-08-29
SI2355822T1 (sl) 2013-02-28
JP6223480B2 (ja) 2017-11-01
EP2540297B1 (en) 2015-04-08
PL2540297T3 (pl) 2015-12-31
HRP20150711T1 (hr) 2015-08-14
ZA201104044B (en) 2012-11-28
CY1116460T1 (el) 2017-03-15
NZ613291A (en) 2014-11-28
CY1113671T1 (el) 2016-07-27
IL256313A (en) 2018-02-28
US8642638B2 (en) 2014-02-04
NZ593467A (en) 2013-07-26
PT2355822E (pt) 2013-01-14
CA2894860C (en) 2018-11-06
US8569354B2 (en) 2013-10-29
US20150265583A1 (en) 2015-09-24
CA2744278A1 (en) 2010-05-27
PT2540297E (pt) 2015-08-26
HK1158520A1 (en) 2012-07-20
HUE037938T2 (hu) 2018-09-28
WO2010059844A1 (en) 2010-05-27
IL212921A0 (en) 2011-07-31
JP2016128442A (ja) 2016-07-14
DK2540297T3 (en) 2015-07-13
HUE026815T2 (en) 2016-07-28
RU2018125456A (ru) 2020-01-13
EP3357495A1 (en) 2018-08-08
IL242034A0 (en) 2015-11-30
US20180271844A1 (en) 2018-09-27
PH12018500023A1 (en) 2019-07-15
IL256140A (en) 2018-02-28
KR20140146216A (ko) 2014-12-24
JP5869653B2 (ja) 2016-02-24
IL242035A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112013003677A2 (pt) uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
EA200802204A1 (ru) Применение ингибиторов dpp iv
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
CL2011002847A1 (es) Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion.
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
ATE543492T1 (de) Behandlung von lungenkrebs
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.

Legal Events

Date Code Title Description
FC Refusal